SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

NanoViricides expects Ebola study of NV-387 to enter Phase IIb

NanoViricides expects its Ebola study of NV-387 to transition to Phase IIb.

NNVC

Related stories